当前位置: X-MOL 学术Leuk. Res. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Chronic Lymphocytic Leukemia in a Young Population
Leukemia Research ( IF 2.7 ) Pub Date : 2021-07-15 , DOI: 10.1016/j.leukres.2021.106668
Salem H Alshemmari 1 , Abdulaziz Hamdah 2 , Ramesh Pandita 2 , Anita Kunhikrishnan 2
Affiliation  

Introduction

Chronic lymphocytic leukemia (CLL) is uncommon in the Middle East. There is limited data on the prognosis and of CLL in this region.

Methods

This was a retrospective study (2009-2020) of consecutively diagnosed patients with CLL at Kuwait Cancer Center. The diagnosis, prognosis, treatment indication, response criteria, and adverse events were recorded per International Workshop on Chronic Lymphocytic Leukemia guidelines.

Results

A total of 219 patients with CLL were enrolled in the study. The crude annual incidence is 0.4 per 100,000. The median follow-up was 120 months. The median age at diagnosis was 59 years, and 32% of patients with CLL were ≤ 55 years of age. Prognostic fluorescence in situ hybridization data were available in 213 cases. del (13q14/13q34) was found in 80 (31%) cases, del (11q) in 23 (10.7%) cases, del (17p) in 11 (5.16%) cases, and trisomy 12 in 46 (21.5%) cases. IGHV mutation status was available in 92 cases, 45 of which (48.9) were mutated and 47 (51.1%) of which were not. The median progression-free survival (PFS) for the entire cohort was 178 months [95% CI: 145-NE].· The median OS was 203 months [95% CIU: 145-NE]. The median PFS for the IGHV mutated cases was not reached [95% CI: 178 – NE]; while the median PFS for the unmutated CLL cases was 24 months [95% CI: 124 – NE].

Conclusion

CLL is a rare hematological malignancy in the Middle East. Our CLL cohort is younger and expresses less del13q, but has similar rates of IGHV mutations.



中文翻译:

年轻人群中的慢性淋巴细胞白血病

介绍

慢性淋巴细胞白血病 (CLL) 在中东并不常见。该地区有关 CLL 预后和预后的数据有限。

方法

这是一项针对科威特癌症中心连续诊断出的 CLL 患者的回顾性研究(2009-2020 年)。根据慢性淋巴细胞白血病国际研讨会指南记录了诊断、预后、治疗适应症、反应标准和不良事件。

结果

共有 219 名 CLL 患者参加了该研究。粗年发病率为每 100,000 人中 0.4 人。中位随访时间为 120 个月。诊断时的中位年龄为 59 岁,32% 的 CLL 患者≤55 岁。在 213 例病例中可获得预后荧光原位杂交数据。del (13q14/13q34) 在 80 (31%) 例中发现,del (11q) 在 23 (10.7%) 例中被发现,del (17p) 在 11 (5.16%) 例中被发现,12 三体在 46 (21.5%) 例中被发现. 在 92 例病例中可获得 IGHV 突变状态,其中 45 例 (48.9) 发生突变,47 例 (51.1%) 未发生突变。整个队列的中位无进展生存期 (PFS) 为 178 个月 [95% CI:145-NE]。·中位 OS 为 203 个月 [95% CIU:145-NE]。未达到 IGHV 突变病例的中位 PFS [95% CI:178 – NE];

结论

CLL 是中东地区罕见的血液系统恶性肿瘤。我们的 CLL 队列更年轻,表达较少的 del13q,但具有相似的 IGHV 突变率。

更新日期:2021-07-15
down
wechat
bug